Gem Pharmaceuticals announced that the Food and Drug Administration has granted Orphan Drug designation to GPX-150 for the treatment of soft tissue sarcoma (STS).

GPX-150 is currently undergoing a Phase 2 clinical trial to assess its efficacy and safety in adult patients with STS as first-line therapy for advanced or metastatic disease. The primary endpoint is progression-free rate at 12 months. Final results are expected to be available by the fourth quarter of 2016.

RELATED: Pexidartinib Designated Breakthrough Therapy for Rare Tumor

STS includes a group of malignancies that affect tissues such as fat, muscles, nerves, and tendons. 

For more information visit